Table 1 Subject and leukapheresis characteristics.

From: Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy

 

Total

N = 76

Patient background

 Age (year)

61 (21–75)

 Sex

  Male

47 (61.8%)

  Female

29 (38.2%)

 Height (cm)

164.3 (145.7–181.1)

 Body weight (kg)

57.2 (39.8–82.0)

 Total blood volume (Nadler) (dL)

41.2 (27.4–51.4)

 Type of apheresis

  Allo-PBSC

6 (7.9%)

  Auto-PBSC

21 (27.6%)

  CAR-T

49 (64.5%)

Laboratory data before leukapheresis

 Hct (%)

30.1 (23.9–46.1)

 Alb (g/dL)

3.7 (2.6–4.7)

 T-Bil (mg/dL)

0.5 (0.3–2.3)

 eGFR (mL/min/1.73m2)

74.3 (27.4–176.1)

Leukapheresis parameters

 Blood volume processed (L)

10.0 (6.0–15.0)

 Duration of apheresis (min)

219 (110–328)

 Dos of ACD-A (mL)

916 (546–1364)

 Dose of 8.5% calcium gluconate (mL)

55 (24–80)

  1. ACD-A, acid citrate dextrose solution A; Alb, albumin; allo-PBSC, allogeneic peripheral blood stem cell harvest; auto-PBSC, autologous peripheral blood stem cell harvest; CAR-T, chimeric antigen receptor T-cell therapy; eGFR, estimated glomerular filtration rate; Hct, hematocrit; iCa, ionized calcium; T-Bil, total bilirubin; TBV, total blood volume; tCa, total calcium. Continuous variables were summarized using medians and ranges, and categorical variables were summarized as counts and percentages. Normal ranges of laboratory values: Hct, 40.7–50.1% for male, 35.1–44.4% for female; Alb, 4.1–5.1 g/dL; T-Bil, 0.4–1.5 mg/dL; eGFR, ≥ 90 ml/min/1.73 m2.
Back to article page